in rough numbers - the ph3 trial is costing like $300-400k per patient. I don’t know how this stacks up against other trials but seems quite high. Anyone want to shed any light on on this?
Ann: Opthea Presents at the Jefferies 2023 Healthcare Conference, page-31
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $409.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.0¢ | $728.0K | 1.935M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 144551 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 6300 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |